CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Bendamustine +1 moredrug
Likely dose
Bendamustine 60 mg/m² IV weekly (days 1, 8, 15 every 5 weeks) with bortezomib 1.5 mg/m² IV weekly (days 1, 8, 15, 22 every 5 weeks)AI-extracted
Key inclusion· 3
  • ✓Symptomatic recurrent or refractory indolent NHL or B-CLL
  • ✓Adequate organ and bone marrow function
  • ✓Karnofsky performance status greater than 50%
Key exclusion· 3
  • ✕Candidates for autologous stem cell transplantation
  • ✕Secondary high-grade lymphoma
  • ✕Concurrent severe medical condition

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00426855
NCT00426855Phase 2Completed
CompareCT.gov

Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study

Peter Moosmann·interventional·Posted Jan 25, 2007·Updated Apr 3, 2015

In Brief

A Phase 2 clinical trial evaluating Bendamustine and Bortezomib for Lymphoma, Non-Hodgkin. Completed, enrolled 12 participants.

Detailed Summary

The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin
Countries--
CollaboratorsKantonsspital Aarau

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 25, 2007
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.4 years ago

Interventions

Bendamustinedrug

starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w

Bortezomibdrug

weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w